Dr. Andrew S. Dothard, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 207
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NC license 2018-00411 -
Internal Medicine Physician
NC license 2018-00411
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health Forsyth Medical Center Winston-Salem, NC
- Novant Health Thomasville Medical Center Thomasville, NC
Medical groups
- Forsyth Memorial Hospital Inc (620 clinicians)
- Novant Health Thomasville Medical Center LLC (103 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 207
- Services billed
- 861
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 219 | 75 |
| Established patient office or other outpatient visit, 30-39 minutes | 78 | 61 |
| New patient office or other outpatient visit, 60-74 minutes | 58 | 58 |
| New patient office or other outpatient visit, 45-59 minutes | 22 | 22 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 73 payments worth $51,222 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $29,370 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $19,779 |
| Daiichi Sankyo Inc. | $1,844 |
| Iovance Biotherapeutics, Inc. | $169 |
| Janssen Scientific Affairs, LLC | $35.29 |
| Ipsen Biopharmaceuticals, Inc | $24.25 |
| Compensation for services other than consulting (speaking, faculty) | $31,150 |
|---|---|
| Consulting Fee | $16,184 |
| Travel and Lodging | $2,390 |
| Food and Beverage | $1,454 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Oct 13, 2025 | Compensation for services other than consulting (speaking, faculty) TAGRISSO · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| AstraZeneca Pharmaceuticals LP Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| Regeneron Healthcare Solutions, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $4,912 |
| Regeneron Healthcare Solutions, Inc. Sep 5, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $4,613 |
| Regeneron Healthcare Solutions, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $3,684 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $3,684 |
| AstraZeneca Pharmaceuticals LP Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,680 |
| AstraZeneca Pharmaceuticals LP Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,680 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $2,636 |
| AstraZeneca Pharmaceuticals LP Nov 21, 2025 | Consulting Fee | $2,010 |
All 37 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $3,684 |
| Daiichi Sankyo Inc. Dec 3, 2025 | Consulting Fee | $1,102 |
| Daiichi Sankyo Inc. Dec 3, 2025 | Consulting Fee | $551 |
| AstraZeneca Pharmaceuticals LP Nov 21, 2025 | Consulting Fee | $2,010 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| AstraZeneca Pharmaceuticals LP Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,680 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $768 |
| AstraZeneca Pharmaceuticals LP Oct 28, 2025 | Travel and Lodging TAGRISSO · Oncology · travel to Abingdon, VA | $210 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $860 |
| AstraZeneca Pharmaceuticals LP Oct 13, 2025 | Compensation for services other than consulting (speaking, faculty) TAGRISSO · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $2,636 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $1,648 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $1,318 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $659 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $330 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $24.00 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $600 |
| Regeneron Healthcare Solutions, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $3,684 |
| Regeneron Healthcare Solutions, Inc. Sep 5, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $4,613 |
| Regeneron Healthcare Solutions, Inc. Sep 5, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $989 |
| Regeneron Healthcare Solutions, Inc. Sep 5, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $330 |
| AstraZeneca Pharmaceuticals LP Jul 30, 2025 | Travel and Lodging travel to Kingsport, TN | $266 |
| AstraZeneca Pharmaceuticals LP Jul 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| Regeneron Healthcare Solutions, Inc. Jun 26, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $155 |
| Regeneron Healthcare Solutions, Inc. Jun 26, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $89.71 |
| Regeneron Healthcare Solutions, Inc. Jun 25, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $155 |
| Regeneron Healthcare Solutions, Inc. Jun 24, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $469 |
| Regeneron Healthcare Solutions, Inc. Jun 18, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $225 |
| Regeneron Healthcare Solutions, Inc. Jun 18, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $25.50 |
| AstraZeneca Pharmaceuticals LP Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,680 |
| Regeneron Healthcare Solutions, Inc. Jun 17, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $263 |
| Regeneron Healthcare Solutions, Inc. Jun 17, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $25.50 |
| Regeneron Healthcare Solutions, Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $563 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to WILMINGTON, NC · in-kind | $329 |
| Regeneron Healthcare Solutions, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $4,912 |
| Regeneron Healthcare Solutions, Inc. Feb 11, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $114 |
| Regeneron Healthcare Solutions, Inc. Feb 11, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TARRYTOWN, NY · in-kind | $40.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $25,062 in research payments for these studies, mostly to the institutions running them.
- A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Daiichi Sankyo Inc. · Recruiting · NCT06362252 - EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma
Novocure GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.